Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Oppenheimer downgraded DexCom (DXCM) to Perform from Outperform without a price target after assuming coverage of the name. The company is doing all it can to offset industry challenges but field ...

Shares of medical device company DexCom (NASDAQ:DXCM) fell 7.4% in the morning session after a short-seller report from Hunterbrook Capital alleged issues with the company's G7 glucose monitoring ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.

Pull requests help you collaborate on code with other people. As pull requests are created, they’ll appear here in a searchable and filterable list. To get started, you should create a pull request.

Next presentation this afternoon is from DexCom, a leader in developing and commercializing continuous glucose monitoring systems for people with diabetes and I'm sure in the future beyond diabetes.